Chemotherapy Omission in ER+/HER2- Breast Cancer With 1-3 Positive Lymph Nodes Receiving Extended Adjuvant Abemaciclib

Trial Details

NCT ID

NCT06341621

Phase

PHASE3

Sponsor

Fudan University

Status

RECRUITING

Cancer Type

HER2 Positive Breast Cancer

Interventions

• 3-year abemaciclib without chemo
• treatment of physician's choice

Locations (sample)

• Shanghai, China|31.22222,121.45806

Key Eligibility Criteria

• women aged 18-80 years old;
• Patient has localized invasive breast carcinoma with1-3 positive lymph nodes, T1-T2，and is ER+/HER2- confirmed by histopathology after early breast…
• Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;
• Has adequate organ function meeting the following criteria: (1) adequate bone marrow function: hemoglobin ≥ 90 g/L (no blood transfusion within 14 …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.